SCHEMBL8277157

SCHEMBL8277157

Cc1ccc(CNC(=O)c2ccc(-c3ccc(OCCc4ccc(Cl)cc4)nn3)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 2/20 0.49
HDAC1 Q13547 2/20 0.49
EPHX2 P34913 2/20 0.48
NPC1 O15118 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
RAB9A P51151 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C19 P33261 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
PPARA Q07869 1/20 0.45
MAPK14 Q16539 1/20 0.45
PSEN1 P49768 1/20 0.45
PSEN2 P49810 1/20 0.45
APH1B Q8WW43 1/20 0.45
NCSTN Q92542 1/20 0.45
APH1A Q96BI3 1/20 0.45
PSENEN Q9NZ42 1/20 0.45
LMNA P02545 2/20 0.44
AKR1C4 P17516 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL692460 0.85 BCL2L1 (0.50) LMNA
SCHEMBL692988 0.81 CTRC (0.46) NPC1MEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL13947380 0.77 MEN1 (0.72) EPHX2NPC1MEN1KMT2ARAB9A
SCHEMBL25872270 0.77 MEN1 (0.72) EPHX2NPC1MEN1KMT2ARAB9A
SCHEMBL693167 0.74 MAOB (0.41) NPC1MEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL692593 0.72 NR4A2 (0.48) MEN1KMT2APPARAAKR1C3
SCHEMBL14009832 0.71 KDM1A (0.55) KDM1AHDAC1EPHX2NPC1MEN1
SCHEMBL14021154 0.71 JAK2 (0.55) KDM1AHDAC1NPC1RAB9A
SCHEMBL692973 0.71 MEN1 (0.47) MEN1KMT2ALMNA
SCHEMBL13932522 0.70 ALDH1A1 (0.78) HDAC1EPHX2MEN1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120129858-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH 2012-05-24 US disclosed
US-20110288093-A1 Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives INSTITUTE FOR ONEWORLD HEALTH 2011-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129858-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES CFTR, PKD1, PKD2 KDM1A 4466/4885HDAC1 2665/4885EPHX2 2296/4885
US-20110288093-A1 Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives SCN1A, CLIC1, CLCN2 KDM1A 3755/4885HDAC1 922/4885EPHX2 1337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.